|
Three clinical trials of Neuragen® have been completed to date with 160 patients.
The graphs below depict a double blind placebo controlled trial by independent researchers at Louisiana State University. 60 subjects experiencing all-cause neuropathic foot pain (top) and a sub group of diabetic neuropathy (bottom) were treated with Neuragen. In both cases greater than 80% of patients received significant relief.
40 subjects with all-cause neuropathic pain in the feet were treated in a LSU double blind placebo controlled trial. The graph below represents the average pain level for all participants before treatment (time=0) and for up to 9 hours after treatment with either Neuragen (blue drops) or placebo (grey triangles). Pain relief with Neuragen was statistically significant over placebo and for up to 8 hours in duration.

Another commonly accepted way to analyze data from pain trials is to compare the number of patients who received at least a 50% reduction in pain level vs. placebo. As shown below, 63% of subjects receiving Neuragen benefited from a 50% or greater reduction in pain, vs. only 15% in the placebo group.
|